Edgar Filing: INVIVO THERAPEUTICS HOLDINGS CORP. - Form 3

INVIVO THERAPEUTICS HOLDINGS CORP.

Form 3

September 03, 2013

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement INVIVO THERAPEUTICS HOLDINGS CORP. [NVIV] Moran Sean F. (Month/Day/Year) 08/22/2013 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) C/O INVIVO THERAPEUTICS (Check all applicable) HOLDINGS CORP., ONE KENDALL SQUARE, SUITE 10% Owner Director B14402 _X__ Officer Other (give title below) (specify below) (Street) 6. Individual or Joint/Group Acting Chief Financial Officer Filing(Check Applicable Line) _X_ Form filed by One Reporting Person CAMBRIDGE, MAÂ 02139 Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 4. Nature of Indirect Beneficial 1. Title of Security 2. Amount of Securities Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) (Instr. 5) Form: Direct (D) or Indirect (Instr. 5) Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

3. Title and Amount of 1. Title of Derivative Security 2. Date Exercisable and 5. 6. Nature of Indirect 4. **Expiration Date** Securities Underlying Conversion Ownership Beneficial Ownership (Instr. 4) (Month/Day/Year) **Derivative Security** or Exercise Form of (Instr. 5) (Instr. 4) Price of Derivative Derivative Security:

Edgar Filing: INVIVO THERAPEUTICS HOLDINGS CORP. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	(1)	10/25/2020	Common Stock	123,227	\$ 1	D	Â
Stock Option (Right to Buy)	(1)	01/04/2022	Common Stock	100,000	\$ 2.6	D	Â
Stock Option (Right to Buy)	(1)	10/10/2022	Common Stock	100,000	\$ 1.31	D	Â
Stock Option (Right to Buy)	(1)	03/22/2023	Common Stock	50,000	\$ 2.48	D	Â

Reporting Owners

Reporting Owner Name / Address	Kelationships				
	Director	10% Owner	Officer	(Other
an Sean F					

Dalatianshin

Moran Sean F.

C/O INVIVO THERAPEUTICS HOLDINGS CORP.
ONE KENDALL SQUARE, SUITE B14402
CAMBRIDGE, MAÂ 02139
 Â Â Acting Chief Financial Officer Â

Signatures

/s/ Sean F.
Moran

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Option vests 25% on the first anniversary of the date of grant, and thereafter in 36 equal monthly installments until fully vested on the fourth anniversary of the date of grant.

Â

Remarks:

Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2